Cumulative TyG-BRI tracks rising cardiovascular risk across CKM stages 0–3
In a prospective cohort of Chinese adults aged 45 years and older, cumulative exposure to TyG-BRI tracked a higher risk of incident cardiovascular disease across Cardiovascular–Kidney–Metabolic syndrome stages 0 through 3. The signal was not a simple straight line. Risk rose most clearly at the upper end of exposure, where participants in the highest quartile carried a substantially greater hazard than those in the lowest quartile.
This matters because the index combines two easily obtained metabolic markers: the triglyceride-glucose index and body roundness index. Together, they capture the metabolic spillover of insulin resistance and central adiposity, two forces that accelerate endothelial dysfunction, atherogenesis, and vascular inflammation. In settings where imaging or specialized biomarker panels are impractical, a cumulative measure built from routine clinical data can offer a more durable picture of cardiometabolic burden than a single baseline value.
The cohort came from the China Health and Retirement Longitudinal Study and included 3,367 adults followed from 2015 to 2020. During follow-up, 638 participants experienced incident CVD, representing 18.9% of the study population. Cox models showed a threshold-dependent association between cumulative TyG-BRI and cardiovascular events. Compared with the lowest quartile, the highest quartile was associated with a hazard ratio of 1.55, with a 95% confidence interval of 1.19 to 2.02. The trend across quartiles was highly significant.
The excess risk concentrated at the top of the exposure range
The pattern was especially important: the risk increase did not spread evenly across all exposure levels. Restricted cubic spline analysis supported a nonlinear relationship, indicating that cumulative TyG-BRI behaved more like a burden marker with a tipping point than a linear dose-response curve. In practical terms, patients carrying the greatest sustained metabolic load appear to move into a distinctly higher-risk zone.
Kaplan-Meier curves widened steadily over time, with cumulative survival probabilities diverging significantly between exposure groups. The log-rank test was highly significant, reinforcing the event separation seen in the regression models. In a real-world clinic, that kind of separation suggests the index may be useful for identifying patients whose metabolic profile is not merely abnormal, but persistently and progressively dangerous.
A single snapshot can miss years of harmful exposure.
The cumulative design is the strength here. Triglycerides and glucose levels fluctuate, as does adiposity, but vascular injury reflects repeated metabolic stress rather than a one-time reading. Chronic exposure to elevated TyG-BRI likely represents sustained insulin resistance, excess free fatty acid flux, adverse lipoprotein remodeling, and low-grade inflammation. Those processes converge on plaque formation, plaque instability, and impaired vascular repair. The biology fits the epidemiology.
Why a cumulative metabolic index may outperform a single measurement
TyG-BRI is attractive because both of its components are accessible in routine care. The triglyceride-glucose index reflects the metabolic consequences of insulin resistance, while body roundness index is designed to better approximate central fat distribution than body mass alone. Their combination may therefore outperform crude anthropometric measures, particularly in older adults in whom sarcopenia, fat redistribution, and metabolic fragility can distort body mass index.
The cumulative version extends that logic. Rather than asking whether a patient crossed a threshold once, it asks whether the patient carried a persistent burden over time. That approach may be especially relevant in CKM syndrome, where metabolic abnormalities, renal dysfunction, and cardiovascular injury reinforce one another. A repeated metabolic insult can amplify arterial stiffness, worsen renal microvascular injury, and deepen the inflammatory milieu that drives atherosclerotic disease.
The study also examined the association across CKM stages 0–3, strengthening the relevance of the findings across a broad cardiometabolic spectrum. Even though the article does not break down the event estimates by every subgroup in the abstract, the authors report that robustness checks through subgroup and sensitivity analyses supported the main result. That makes the central observation harder to dismiss as an artifact of one narrow demographic slice or a fragile modeling choice.
What this means for everyday risk stratification
For clinicians, the key question is whether a routinely calculable index can improve risk recognition before overt cardiovascular disease appears. This cohort suggests that cumulative TyG-BRI may do exactly that, especially in adults already carrying a substantial metabolic load. Because the components rely on standard laboratory and anthropometric measures, the index could be incorporated into population studies, primary care workflows, or preventive cardiometabolic programs without major technical barriers.
Its potential use is most compelling in older adults with overlapping risk factors. In this group, the usual binary labels of “normal” and “abnormal” often fail to capture the burden of years spent in a pro-atherogenic state. A cumulative metric may better reflect the chronic exposure that matters most for downstream vascular events.
Still, the study does not establish clinical thresholds for intervention, and it does not prove that lowering TyG-BRI will reduce cardiovascular events. The observed association supports risk stratification, not treatment assignment. The next step is validation in other populations, along with work that tests whether the index adds value beyond established calculators and whether it improves classification meaningfully in routine practice.
A risk signal built from routine measurements
The strongest message from this CHARLS analysis is straightforward: long-term exposure to an adverse triglyceride-glucose and adiposity profile carried a higher incidence of cardiovascular disease, and the excess risk became most visible at the top quartile of cumulative burden. For populations with high cardiometabolic risk, that pattern is clinically useful because it turns common measurements into a longitudinal warning signal.
The study’s own boundaries remain important. It was conducted in Chinese adults aged 45 years and older, and its findings need external confirmation before cumTyG-BRI can be considered broadly transferable. The article also leaves open the question of how the index performs alongside newer risk equations, whether it improves discrimination beyond conventional markers, and how often it should be measured in practice. Those unanswered points will determine whether this metric stays a promising epidemiologic marker or becomes part of routine cardiovascular prevention.